SCHEMBL29461541

SCHEMBL29461541

CC(C)C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(=O)O

nearest known ligand 0.70

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ NPY1R P25929 2/20 0.70
▸ NPY2R P49146 2/20 0.70
▸ NPY4R P50391 2/20 0.70
▸ NPY5R Q15761 2/20 0.70
▸ CXCR4 P61073 7/20 0.69
▸ C5AR1 P21730 1/20 0.64
▸ IL23R Q5VWK5 1/20 0.64
▸ GLP1R P43220 4/20 0.63
▸ GCGR P47871 3/20 0.63
▸ TFPI P10646 2/20 0.63
▸ NMBR P28336 1/20 0.63
▸ GRPR P30550 1/20 0.63
▸ GIPR P48546 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29351718 0.93 NPY1R (0.71) NPY1RNPY2RNPY4RNPY5RCXCR4
SCHEMBL31182610 0.92 NPY2R (0.75) NPY1RNPY2RNPY4RNPY5RCXCR4
SCHEMBL29949651 0.91 NPY1R (0.67) NPY1RNPY2RNPY4RNPY5RGLP1R
Dynorphin A (1-17) SCHEMBL30248363 0.91 NPY1R (0.68) NPY1RNPY2RNPY4RNPY5RCXCR4
Dynorphin A (1-17) SCHEMBL31331988 0.91 NPY1R (0.68) NPY1RNPY2RNPY4RNPY5RCXCR4
SCHEMBL30658277 0.91 NPY2R (0.75) NPY1RNPY2RNPY4RNPY5RCXCR4
SCHEMBL29638062 0.91 GLP1R (0.74) NPY1RNPY2RNPY4RNPY5RCXCR4
SCHEMBL29638067 0.91 GLP1R (0.74) NPY1RNPY2RNPY4RNPY5RCXCR4
SCHEMBL31182660 0.90 NPY1R (0.70) NPY1RNPY2RNPY4RNPY5RC5AR1
SCHEMBL30633122 0.90 NPY2R (0.70) NPY1RNPY2RNPY4RNPY5RCXCR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12629409-B2 Vaccine GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2026-05-19 — — US disclosed
US-20240226261-A9 VACCINE GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2024-07-11 — — US disclosed
US-20240131136-A1 VACCINE GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2024-04-25 — — US disclosed
US-11844828-B2 Vaccine GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2023-12-19 — — US disclosed
US-20230248816-A9 PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2023-08-10 — — US disclosed
US-20230066762-A1 IMMUNOGENIC COMPOSITION GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2023-03-02 — — US disclosed
US-20220288190-A1 PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2022-09-15 — — US disclosed
US-20220152182-A1 VACCINE GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2022-05-19 — — US disclosed
US-11266731-B2 Vaccine GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2022-03-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220288190-A1 PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE CFD, PEPD, SERPINA6 NPY1R 3081/4885NPY2R 2991/4885NPY4R 3062/4885
US-20230248816-A9 PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE CFD, PEPD, SERPINA6 NPY1R 3081/4885NPY2R 2991/4885NPY4R 3062/4885
US-12629409-B2 Vaccine MRPL21, STT3B, CD47 NPY1R 270/4885NPY2R 658/4885NPY4R 1069/4885
US-20230066762-A1 IMMUNOGENIC COMPOSITION CXCL10, CCL2, CCL11 NPY1R 3388/4885NPY2R 3202/4885NPY4R 3821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback